Prescribing Patterns and Clinician Perceptions of GLP-1 Receptor Agonists Beyond Diabetes Management: A Cross-Sectional Study
Keywords:
GLP-1 receptor agonists; prescribing patterns; clinician perceptions; obesity; gastrointestinal adverse effects; cardiovascular riskAbstract
Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly used beyond diabetes, yet real-world prescribing behaviors and clinician perceptions remain heterogeneous, particularly regarding gastrointestinal tolerability and cardiometabolic benefit. Objective: To characterize prescribing patterns and clinician perceptions of GLP-1–based therapies beyond diabetes management and identify factors associated with beyond-diabetes prescribing. Methods: A cross-sectional clinician survey (N=160) assessed clinician characteristics, prescribing behaviors, titration strategy, gastrointestinal adverse-event (GI-AE) discontinuation, perceived benefits (weight, cardiovascular, heart failure), perceived GI risk, and implementation barriers. The primary outcome was clinician-reported prescribing beyond diabetes (yes/no). Associations were evaluated using chi-square tests and multivariable logistic regression with odds ratios (aORs) and 95% confidence intervals (CIs). Results: Overall, 86.3% prescribed GLP-1–based therapy and 68.1% prescribed beyond diabetes. Among prescribers, 37.7% used slower-than-label titration due to GI tolerability and 28.3% reported GI-AE discontinuation in the prior 6 months. Beyond-diabetes prescribing was independently associated with formal incretin training (aOR 2.48, 95% CI 1.23–5.00) and endocrinology vs family medicine specialty (aOR 3.12, 95% CI 1.27–7.69), while higher perceived GI-AE burden (aOR 0.71 per Likert point, 95% CI 0.52–0.98) and access-barrier severity (aOR 0.66 per Likert point, 95% CI 0.44–0.98) reduced the odds of beyond-diabetes prescribing. Conclusion: Beyond-diabetes GLP-1 prescribing is common and is shaped by training and specialty context, but constrained by GI tolerability and access barriers, supporting targeted education and implementation strategies.
References
1. Abu-Nejim H, Becker RC. Current perspectives on GLP-1 agonists in contemporary clinical practice from science and mechanistic foundations to optimal translation. Curr Atheroscler Rep. 2025;27:99. doi:10.1007/s11883-025-01350-7.
2. Al Qassab M, Mneimneh M, Jradi A, Derbas B, Dabboussi D, Khoury Baini J, et al. The expanding role of GLP-1 receptor agonists: advancing clinical outcomes in metabolic and mental health. Curr Issues Mol Biol. 2025;47(4):285. doi:10.3390/cimb47040285.
3. Alexiadou K, Hartley A, Tan TMM, Khamis R. The cardiovascular effects of GLP-1 receptor agonists beyond obesity and type 2 diabetes: an anti-atherosclerotic action. Trends Cardiovasc Med. 2024;34(8):552-7. doi:10.1016/j.tcm.2024.03.003.
4. Arredouani A. GLP-1 receptor agonists, are we witnessing the emergence of a paradigm shift for neuro-cardio-metabolic disorders? Pharmacol Ther. 2025;269:108824. doi:10.1016/j.pharmthera.2025.108824.
5. Bensignor MO, Wolf JM, Rudser KD, Kelly AS, Arslanian S. Glucagon-like peptide-1 receptor agonist prescribing patterns in adolescents with type 2 diabetes. Diabetes Obes Metab. 2022;24(7):1380-4. doi:10.1111/dom.14681.
6. Camilleri M, Lupianez-Merly C. Effects of GLP-1 and other gut hormone receptors on the gastrointestinal tract and implications in clinical practice. Am J Gastroenterol. 2024;119(6):1028-37.
7. Han SH, Ockerman K, Furnas H, Mars P, Klenke A, Ching J, et al. Practice patterns and perspectives of the off-label use of GLP-1 agonists for cosmetic weight loss. Aesthetic Surg J. 2024;44(4):NP279-NP306.
8. Honigberg MC, Chang L-S, McGuire DK, Plutzky J, Aroda VR, Vaduganathan M. Use of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes and cardiovascular disease. JAMA Cardiol. 2020;5(10):1182.
9. Laurindo LF, Barbalho SM, Guiguer EL, Soares de Souza MS, de Souza GA, Fidalgo TM, et al. GLP-1a: going beyond traditional use. Int J Mol Sci. 2022;23(2):739. doi:10.3390/ijms23020739.
10. Li P, Varghese JS, Shah MK, Galindo RJ, Pasquel FJ, Ali MK, Shao H. Prescribing trends of glucagon-like peptide 1 receptor agonists for type 2 diabetes or obesity. JAMA Netw Open. 2025;8(10):e2540890. doi:10.1001/jamanetworkopen.2025.40890.
11. Moiz A, Filion KB, Tsoukas MA, Yu OHY, Peters TM, Eisenberg MJ. The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions. EClinicalMedicine. 2025;86:103363.
12. Nashwan AJ, Abukhadijah HJ, Karavadi V, Aqtam I, Ibraheem A, Palanivelu P, et al. Exploring glucagon-like peptide-1 receptor agonists usage among non-diabetic healthcare providers: a cross-sectional multi-country study. Health Sci Rep. 2025;8(4). doi:10.1002/hsr2.70638.
13. Ntelis S, Wojeck BS. Obesity medications beyond glucose control and weight reduction: updates on the expanding benefits, clinical challenges, and future directions. Curr Hypertens Rep. 2025;28(1):5. doi:10.1007/s11906-025-01349-0.
14. Sheth K, Kim S, Porterfield L, Virani SS, Wadhwani S, Vaughan EM. The expanding scope of GLP-1 receptor agonists: six uses beyond diabetes. Curr Atheroscler Rep. 2025. doi:10.1007/s11883-025-01319-6.
15. Spinelli KJ, Oakes AH, Chiu S-T, Imboden MT, Miller A, Jain S, et al. Health disparity clusters of off label prescriptions for glucagon-like peptide 1 receptor agonists. Am J Med Open. 2025;13:100100.
16. Ukhanova M, Wozny JS, Truong CN, Ghosh L, Krause T. Trends in glucagon-like peptide 1 receptor agonist prescribing patterns. Am J Manag Care. 2025;31(8):e228-e34.
17. Watanabe JH, Kwon J, Nan B, Reikes A. Trends in glucagon-like peptide 1 receptor agonist use, 2014 to 2022. J Am Pharm Assoc. 2024;64(1):133-8. doi:10.1016/j.japh.2023.10.002.
18. Wilbon SS, Kolonin MG. GLP1 receptor agonists effects beyond obesity and diabetes. Cells. 2023;13(1):65.
19. Xu D, Nair A, Sigston C, Ho C, Li J, Yang D, et al. Potential roles of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in nondiabetic populations. Cardiovasc Ther. 2022;2022:6820377. doi:10.1155/2022/6820377.
20. Zhao X, Wang M, Wen Z, Lu Z, Cui L, Fu C, et al. GLP-1 receptor agonists: beyond their pancreatic effects. Front Endocrinol (Lausanne). 2021;12:721135. doi:10.3389/fendo.2021.721135.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Mahrukh Badar, Fazeela Tahir, Sana Majeed Rizvi (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright is retained by the Author(s). Published in JPMHR under the Creative Commons Attribution 4.0 International License (CC BY 4.0). Unrestricted reuse is permitted with proper attribution to the author(s) and source.
